期刊文献+

儿童急性淋巴细胞白血病多中心治疗研究的体会及思考 被引量:2

原文传递
导出
摘要 全国性多中心协作组——中国儿童白血病协作组(Chinese Children's Leukemia Group,CCLG)已成立6年.在全国血液界同道和国家新农合及社保政策的支持下,在科技部国家科技支撑计划项目的资助下,2008年4月,由首都医科大学附属北京儿童医院牵头建立了全国性多中心CCLG,联合国内12家三级甲等医院(香港中文大学威尔斯亲王医院、苏州大学附属儿童医院、中国医学科学院中国协和医科大学血液学研究所血液病医院、重庆医科大学附属儿童医院、四川大学华西第二医院、复旦大学儿科医院、首都儿科研究所附属儿童医院、北京大学人民医院、华中科技大学同济医学院附属协和医院、中国人民解放军总医院、中国人民解放军海军总医院、哈尔滨市儿童医院),在CCLG成员的共同努力下,克服医疗资源短缺、技术力量薄弱等困难,使国内儿童急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)的整体治疗和研究水平有了很大提高,既造福于广大白血病患儿及其家庭,同时,亦向世界展示了我国儿童ALL的首个多中心、大样本研究成果,使国内治疗儿童ALL的疗效可与国际优秀治疗组相媲美.
出处 《中华妇幼临床医学杂志(电子版)》 CAS 2014年第3期1-4,共4页 Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)
基金 国家科技支撑计划项目(2007BAI04B03) 国家自然科学基金资助项目(81170504 81200392) 北京市卫生系统高层次卫生技术人才培养计划项目(2011-3-049)
  • 相关文献

参考文献3

二级参考文献39

  • 1Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia, lancet Oncol, 2008, 9 : 257- 268.
  • 2Fronkova E, Mejstrikova E, Avigad S, et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia, 2008, 22: 989-997.
  • 3Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood, 2007, 110: 1607-1611.
  • 4Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors : a Children's Oncology Group study. Blood, 2008, 111 : 5477-5485.
  • 5Mitchell CD, Richar'ds SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone in childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council MRC ALL97 randomized trial. Br J Haematol, 2005, 129: 734-745.
  • 6Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisolone and daily oral versus weekly intravenous mercaptopurine tor patients with standard risk acute lymphoblastic leukaemia. Blood, 2003, 101 : 3809-3817.
  • 7Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med, 2009, 360 : 2730- 2741.
  • 8Chauvenet AR, Martin PL, Devidas M, et al. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. Blood, 2007, 110 : 1105-1111.
  • 9Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but falls to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 Study for standard-risk acute lymphoblastic leukaemia, reported by the Children's Oncology Group. Blood, 2006, 108 : 1165-1173.
  • 10Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA, 2007, 297: 1207-1215.

共引文献26

同被引文献13

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部